Bausch Health Companies Inc (BHC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Bausch Health Companies Inc stock $24.54, price $8.18, upside +200.0%, quality 49 out of 100. Rating: strongly undervalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $4.32 – $29.47 · fair‑value band $6.74 – $46.66 · the $8.18 price screens below the $24.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Bausch Health Companies in your weekly email
Every Wednesday you see whether Bausch Health Companies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Show moreShow less
The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.
The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Stock analysis
Bausch Health Companies Inc (BHC) currently trades at $8.18, while our model-based Fair Value estimate is $24.54, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $110.71 per share, and 17 of the 20 models we run sit above the $8.18 price.
Bear case: the Earnings-Based group reads lowest at $8.09, and 3 of the 20 models stay below the price. Data coverage for this calculation is low.
Scenario range: $6.74 (bear) to $46.66 (bull), the price of $8.18 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Bausch Health Companies Inc reported revenue of $10.4B in FY2025 versus $8.4B in FY2021, a compound +5.5%/yr. Reported net income was $160M in FY2025.
Key figures
Market cap $3.1B Mid · P/S ratio 0.31 · EPS (TTM) $−2.95 · Net margin −10.1% · Return on equity 43.6% · Return on assets (EBIT) 4.2% (5-year average) · Operating margin 27.2% · Revenue (TTM) $10.9B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (medium confidence).
What moves the price
The share trades about 8% below its 52-week high and 85% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, BHC screens cheaper than that median.
Fair Value models
Bear$6.74Fair Value $24.54Bull$46.66
Price $8.18 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 2 officers or directors sold shares worth $391,690 and none bought.
SaleAimee J. LenarPresident, US Pharma36,827 shares at $7.03$258,894Aug 19, 202610b5-1 plan
SaleFrank D. LeeDirector24,456 shares at $5.43$132,796May 19, 202610b5-1 plan
SaleSeana CarsonEVP, General Counsel2× since Feb 27, 2026: 19,664 shares, avg. $5.85$115,040Mar 3, 202610b5-1 plan
BuyPAULSON & CO. INC.10% owner2,500,000 shares at $6.25$15.6MNov 25, 2025
Plus 18 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic). Over 10 years: +0.0% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.4% (2020) → 21.3% (2025)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.9% a year for the price and −1.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (88 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Sustained year-over-year growth in revenue and adjusted EBITDA marks the core strength, while substantial debt and negative equity remain the primary weakness in a competitive market.
Main risk: Substantial debt combined with negative equity threatens the company's financial stability and operational flexibility in generics manufacturing.
Bausch Health's core business has delivered thirteen consecutive quarters of year-over-year revenue and adjusted EBITDA growth under its CEO, who now also serves as interim head of the majority-owned Bausch + Lomb unit that plans to raise its 2026 outlook. At the same time the parent carries substantial debt and continues to weigh options for its controlling stake in the eye-care company. Will closer operational ties between the two strengthen results more than they complicate governance and value realization?
Compare Bausch Health Companies Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets0.6% · Below median
Net margin (12 months)−10.1% · Bottom 25%
Operating margin (12 months)27.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)12.7% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bausch Health Companies Inc Fair Value". https://www.fairvalue-calculator.com/stock/BHC
Frequently asked questions
Is Bausch Health Companies Inc (BHC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $24.54 versus a price of $8.18, about +200% upside (undervalued).
What is the fair value of BHC?
Our model-based fair value for Bausch Health Companies Inc is $24.54 (as of Nov 4, 2026), built from audited fundamentals. The current price: $8.18.
What is the quality score of BHC?
Bausch Health Companies Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bausch Health Companies Inc (BHC)?
Our model-based price target is the fair value of $24.54 (as of Nov 4, 2026) from 21 valuation models. Cautious scenario $6.74, optimistic scenario $46.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Bausch Health Companies Inc stock forecast for 2026?
Our models put fair value at $24.54, about +200% upside versus a price of $8.18 (undervalued). Cautious scenario $6.74, optimistic scenario $46.66. The calculation is refreshed regularly with new filings.
What is the revenue of Bausch Health Companies Inc (BHC)?
Bausch Health Companies Inc reported trailing-twelve-month revenue of about $10.9B (latest available figure, as of Nov 4, 2026).
What growth is priced into Bausch Health Companies Inc (BHC)?
For today's price to be fair in a discounted-cash-flow model, Bausch Health Companies Inc would have to grow free cash flow by +8.4 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of BHC use?
Our models discount Bausch Health Companies Inc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.37, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bausch Health Companies Inc that is +8.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Bausch Health Companies Inc (BHC) delivered so far?
Over the past 5 years revenue at Bausch Health Companies Inc grew +5.4 % a year. The price currently implies free-cash-flow growth of +8.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bausch Health Companies Inc (BHC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Bausch Health Companies Inc (+8.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bausch Health Companies Inc (BHC)?
The free-cash-flow yield on the price is 32.43 %: that much free cash flow Bausch Health Companies Inc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bausch Health Companies Inc (BHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bausch Health Companies Inc it is $24.54 per share (as of Nov 4, 2026), against a price of $8.18. It is the blended result of 21 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Bausch Health Companies Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, BHC trades below its calculated fair value: price $8.18, fair value $24.54, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BHC?
No. The price is what the market pays today ($8.18); the fair value is what the company's own numbers justify ($24.54). For Bausch Health Companies Inc the two are $16.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bausch Health Companies Inc worth?
The market values Bausch Health Companies Inc at about $3.1B (market capitalisation, as of Nov 4, 2026). Per share that is $8.18; our models calculate a fair value of $24.54 per share.
What do the bullish and bearish scenarios say about BHC?
Our models span a range for Bausch Health Companies Inc: cautious scenario $6.74, base $24.54, optimistic $46.66 per share (as of Nov 4, 2026, price $8.18). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BHC?
The PEG ratio of Bausch Health Companies Inc is 0.01 (P/E divided by earnings growth, as of Nov 4, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Bausch Health Companies Inc (BHC)?
Balance-sheet figures for Bausch Health Companies Inc (as of Nov 4, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is BHC from its 52-week high?
Bausch Health Companies Inc trades at $8.18, about 8% below its 52-week high of $8.91 and 85% above the low of $4.43 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $24.54 is for.
Which stocks are comparable to Bausch Health Companies Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bausch Health Companies Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $8.18, calculated fair value $24.54 (+200%), Quality Score 49/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BHC calculated?
We run Bausch Health Companies Inc through 21 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $24.54 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bausch Health Companies Inc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bausch Health Companies Inc (BHC)?
The closing price on Nov 6, 2026 was $8.18. Our model-based fair value is $24.54, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bausch Health Companies Inc right now?
The large discount to fair value meets weak quality (49/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide ($6.74 to $46.66). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Bausch Health Companies Inc
How large is the market capitalisation of Bausch Health Companies Inc (BHC)?
The market capitalisation of Bausch Health Companies Inc is $3.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bausch Health Companies Inc (BHC)?
The price-to-sales ratio of Bausch Health Companies Inc is 0.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bausch Health Companies Inc (BHC)?
Earnings per share at Bausch Health Companies Inc are $−2.95. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bausch Health Companies Inc (BHC)?
The net margin of Bausch Health Companies Inc is −10.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bausch Health Companies Inc (BHC)?
The return on equity (ROE) of Bausch Health Companies Inc is 43.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bausch Health Companies Inc (BHC)?
On an EBIT basis the return on assets of Bausch Health Companies Inc is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bausch Health Companies Inc (BHC)?
The operating margin of Bausch Health Companies Inc is 27.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bausch Health Companies Inc (BHC)?
Revenue at Bausch Health Companies Inc is growing +12.7% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bausch Health Companies Inc (BHC)?
Earnings per share at Bausch Health Companies Inc are growing +70.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bausch Health Companies Inc (BHC) carry?
The net debt of Bausch Health Companies Inc is $19.9B (fiscal year 2025, ≈ 19.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bausch Health Companies Inc in the live analysis
One click puts Bausch Health Companies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026